Pharmacoeconomics and Outcomes Research Iberia-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2024

  1. Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain

    Cancers, Vol. 16, Núm. 13